Drug Profile
Dronabinol/palmitoylethanolamide - SciSparc
Alternative Names: SCI-110; THX OSA01; THX RS01; THX-110; THX-TS01Latest Information Update: 13 Mar 2024
Price :
$50
*
At a glance
- Originator Therapix Biosciences
- Developer SciSparc; The Israeli Medical Center for Alzheimer's
- Class Amides; Analgesics; Anti-inflammatories; Antidementias; Antiemetics; Antineoplastics; Antivirals; Appetite stimulants; Behavioural disorder therapies; Cannabinoids; Chromans; Ethanolamines; Muscle relaxants; Neuroprotectants; Non-opioid analgesics; Palmitic acids; Sleep disorder therapies; Small molecules
- Mechanism of Action Cannabinoid receptor agonists; Cannabinoid receptor CB1 agonists; Cannabinoid receptor CB2 agonists; G-protein-coupled receptor 55 modulators; Peroxisome proliferator-activated receptor alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Agitation; Alzheimer's disease; Gilles de la Tourette's syndrome; Sleep apnoea syndrome
- No development reported Back pain
Most Recent Events
- 07 Mar 2024 SciSparc has patent protection for composition of cannabinoids and n-acylethanolamines and methods of use in cannabinoid-treated conditions in Austria, Belgium, Denmark, France, Germany, Ireland, Italy, Netherlands, Norway, Poland, Spain, Sweden, Switzerland, Liechtenstein and the UK
- 07 Mar 2024 SciSparc has patent protection for composition of cannabinoids and n-acylethanolamines and methods of use in cannabinoid-treated conditions in Japan and other jurisdictions
- 24 Oct 2023 SciSparc has patent protection for Dronabinol/palmitoylethanolamide covering combinations of cannabinoids and N-Acylethanolamines in Australia